Anticandidal Effect of Polygonum cuspidatum on C. albicans Biofilm Formation

  • Lee, Heung-Shick (Department of Biotechnology and Bioinformatics, Korea University) ;
  • Kim, Youn-Hee (Laboratory of Biochemistry, Department of Oriental Medicine, Semyung University)
  • Received : 2011.12.30
  • Accepted : 2012.01.20
  • Published : 2012.02.25

Abstract

Candida albicans is a common opportunistic pathogen and is frequently associated with biofilm formation occurring on the surfaces of host tissues and medical devices. On account of the distinct resistance of C. albicans biofilms to the conventional antifungal agents, new strategies are required to cope with these infections. The root of Polygonum cuspidatum has been used for medicinal purposes in East Asia. The aim of this study was to assess the anticandidal potential of the P. cuspidatum ethanol extract by evaluating biofilm formation, integrity of the cell membranes of C. albicans and adhesion of C. albicans cells to polystyrene surfaces. The growth and development of the biofilm was assessed using an XTT reduction assay, and the extract (0.39 mg/ml) significantly reduced ($41.1{\pm}17.8%$) biofilm formation of 11 C. albicans strains. The extract damaged the cell membranes of C. albicans and remarkably inhibited cell adhesion to polystyrene surfaces. The plant extract displayed fungistatic activity without significant hemolytic activity. Based on the results of this study, the P. cuspidatum extract has promising potential for use in treating biofilm-associated Candida infection.

Keywords

References

  1. Krcmery, V., Barmes, A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 50: 243-260, 2002. https://doi.org/10.1053/jhin.2001.1151
  2. Haynes, K. Virulence in Candida species. Trends Microbiol 9: 591-596, 2001. https://doi.org/10.1016/S0966-842X(01)02237-5
  3. Ramage, G., Martinez, J.P., Lopez-Ribot, J.L. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 6: 979-986, 2006. https://doi.org/10.1111/j.1567-1364.2006.00117.x
  4. Chandra, J., Kuhn, D.M., Mukherjee, P.K., Hoyer, L.L., McCormick, T., Ghannoum, M.A. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183: 5385-5394, 2001. https://doi.org/10.1128/JB.183.18.5385-5394.2001
  5. Thein, Z.M., Samaranayake, Y.H., Samaranayake, L.P. In vitro biofilm formation of Candida albicans and non-albicans Candida species under dynamic and anaerobic conditions. Arch Oral Biol 52: 761-767, 2007. https://doi.org/10.1016/j.archoralbio.2007.01.009
  6. Oliver, B.G., Silver, P.M., Marie, C., Hoot, S.J., Leyde, S.E., White, T.C. Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiol 154: 960-970, 2008. https://doi.org/10.1099/mic.0.2007/013805-0
  7. Mahmoud, A.G., Louis, B.R. Antifungal agents: mode of action, mechanism of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12: 501-517, 1999.
  8. Guarrera, P.M. Traditional phytotherapy in central Italy. Fitotherapia 76: 1-25, 2005. https://doi.org/10.1016/j.fitote.2004.09.006
  9. Park, C.S., Lee, Y.C., Kim, J.D., Kim, H.M., Kim, C.H. Inhibitory effects of Polygonum cuspidatum water extract (PCWE) and its component resveratrol on acyl-coenzyme A-cholesterol acyltransferase activity for cholesteryl ester synthesis in HepG2 cells. Vascul Pharmacol 40: 279-284, 2004. https://doi.org/10.1016/j.vph.2004.01.003
  10. Bralley, E.E., Greenspan, P., Hargrove, J.L., Wicker, L., Hartle, D.K. Topical anti-inflammatory activity of Polygonum cuspidatum extract in the TPA model of mouse ear inflammation. J Inflamm 5: 1-7, 2008. https://doi.org/10.1186/1476-9255-5-1
  11. Xiao, K., Xuan, L., Xu, Y., Bai, D., Zhong, D. Constituents from Polygonum cuspidatum. Chem Pharm Bull 50: 605-608, 2002. https://doi.org/10.1248/cpb.50.605
  12. Park, S.J., Choi, S.J., Shin, W.S., Lee, H.M., Lee, K.S., Lee, K.H. Relationship between biofilm formation ability and virulence of Candida albicans. J Bacteriol Virol 39: 119-124, 2009. https://doi.org/10.4167/jbv.2009.39.2.119
  13. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3rd edn. M27-A3. CLSI, Wayne, PA. 2008.
  14. Liu, M., Seidel, V., Katerere, D.R., Gray, A.I. Colorimetric broth microdilution method for the antifungal screening of plant extracts against yeast. Methods 42: 325-329, 2007. https://doi.org/10.1016/j.ymeth.2007.02.013
  15. Ramage, G., Vande-Walle, K., Wickes, B.L., Lopez-Ribot, J.L. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45: 2475-2479, 2001. https://doi.org/10.1128/AAC.45.9.2475-2479.2001
  16. Roling, E.E., Klepser, M.E., Wasson, A., Lewes, R.E., Ernst, E.J., Pfaller, M.A. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbial Infec Dis 43: 13-17, 2002. https://doi.org/10.1016/S0732-8893(02)00361-9
  17. Sharma, P., Sharma, J.D. In vitro hemolysis of human erythrocytes - by plant extracts with antiplasmodial activity. 74: 3239-3243, 2001.
  18. Pina-Vaz, C., Sansonetty, F., Rodrigues, A.G., Costa-Oliveira, S., Tavares, C., Martinez-de-Oliveira, J. Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin Microbiol Infect 7: 609-618, 2001. https://doi.org/10.1046/j.1198-743x.2001.00307.x
  19. Newman, D.J., Cragg, G.M., Snader, K.M. Natural products as sources of new drugs over the period. J Nat Prod 66: 1022-1037, 2003. https://doi.org/10.1021/np030096l
  20. Calderone, R.A., Fonzi, W.A. Virulence factors of Candida albicans. Trends Microbiol 9: 327-335, 2001. https://doi.org/10.1016/S0966-842X(01)02094-7
  21. Martin, S.W., Douglas, L.M., Konopka, J.B. Cell cycle dynamics and quorum sensing in Candida albicans chlamydospores care distinct from budding and hyphal growth. Eukaryotic cell 4: 1191-1202, 2005. https://doi.org/10.1128/EC.4.7.1191-1202.2005
  22. Kumamoto, C.A. Candida biofilms. Curr Opin Microbiol 5: 608-611, 2002. https://doi.org/10.1016/S1369-5274(02)00371-5
  23. Hoyer, L.L. The ALS gene family of Candida albicans. Trends Microbiol 9: 176-180, 2001. https://doi.org/10.1016/S0966-842X(01)01984-9
  24. Karkowsk-Kuleta, J., Rapala-Kozik, M., Kozik, A. Fungi pathogenic to humans: molecular bases of virulence of Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus. Acta Biochim Pol 56: 211-224, 2009.
  25. Ruiz-Herrera, J., Elorza, M.V., Valentin, E., Sentandreu, R. Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity. FEMS Yeast Res 6: 14-29, 2006. https://doi.org/10.1111/j.1567-1364.2005.00017.x